HTAC interim recommendation on the use of casirivimab+imdevimab for the treatment of COVID-19 On 24 December 2021, the Secretary of Health approved and signed the Health Technology Assessment Council (HTAC) interim recommendation for the government not to finance casirivimab+imdevimab for the treatment of COVID-19. The Philippine Food and Drug Administration (FDA) issued an Emergency Use Authorization continue reading : Use of Casirivimab + Imdevimab for the Treatment of COVID-19
Tenofovir/Lamivudine/Dolutegravir (TLD) for Treatment-Naive and Treatment-Experienced Adolescents and Adults Living with HIV
Date of publication: August 24, 2021 Approved by the Secretary of Health: September 01, 2021 Evidence Summary: Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV Advisory on non-inclusion in PNF: https://bit.ly/PR_TLD HTAC Recommendation Review:
Effectiveness and Safety of Pazopanib in the Management of Metastatic Soft Tissue Sarcoma Post-Chemotherapy
Evidence Summary: effectiveness and safety of pazopanib in the management of metastatic soft tissue sarcoma post-chemotherapy